Evercore ISI started coverage on shares of resTORbio (NASDAQ:TORC) in a research report released on Tuesday, February 20th, Marketbeat.com reports. The firm issued an outperform rating and a $28.00 price target on the stock.
resTORbio (TORC) traded down $0.37 during midday trading on Tuesday, reaching $15.08. 247,804 shares of the company traded hands, compared to its average volume of 115,397. resTORbio has a twelve month low of $14.56 and a twelve month high of $21.10.
In related news, major shareholder Puretech Health Llc purchased 233,333 shares of the business’s stock in a transaction that occurred on Tuesday, January 30th. The shares were bought at an average cost of $15.00 per share, with a total value of $3,499,995.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Orbimed Advisors Llc purchased 533,333 shares of the business’s stock in a transaction that occurred on Tuesday, January 30th. The stock was bought at an average cost of $15.00 per share, for a total transaction of $7,999,995.00. The disclosure for this purchase can be found here.
ILLEGAL ACTIVITY WARNING: “resTORbio (NASDAQ:TORC) Earns Outperform Rating from Analysts at Evercore ISI” was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.thelincolnianonline.com/2018/03/14/restorbio-torc-coverage-initiated-at-evercore-isi.html.
resTORbio, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. It focuses on the mechanistic target of rapamycin (mTOR) pathway that regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1 (TORC1).
Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with MarketBeat.com's FREE daily email newsletter.